Salvage therapy in chronic graft versus host disease

Chronic Graft Versus Host Disease: Interdisciplinary Management

Volumn , Issue , 2009, Pages 134-145

  Greinix, Hildegard T ^a   Antin, Joseph H ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950539573     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511576751.014     Document Type: Chapter

References (93)

1. Koc S, Leisenring W, Flowers ME, et al Therapy for chronic graft- versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100:48-51.
2. Sullivan KM, Witherspoon RP, Storb R, et al Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-vs-host disease. Blood. 1988;72:555-561.
3. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus- host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981;57:267-276.
4. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-vs-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72:546-554.
5. Deeg HJ, Socie G, Schoch G, et al Malignancies after marrow transplantation for aplastic anemia and Fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood. 1996;87:386-392.
6. Goto T, Kino T, Hatanaka H, et al. FK506: historical perspectives. Transplant Proc. 1991;23:2713-2717.
7. Crum A, Woude V, Bierer E. Immunosuppression and immu- nophilin ligands: cyclosporine A, FK-506 and rapamycin. In: Ferrara JLM, Deeg JH, Burakoff SJ, eds. Graft-versus-host disease. Marcel Dekker, New York, 1996:111-149.
8. Zeiser R, Nguyen VH, Beilhack A, et al Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood. 2006;108:390-399.
9. Baan CC, van der Mast BJ, Klepper M, et al. Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cells. Transplantation. 2005;80:110-117.
10. Tzakis AG, Abu-Elmagd K, Fung JJ, et al FK506 rescue in chronic graft-versus-host disease after bone marrow transplantation. Transplant Proc. 1991;23:3225-3227.
11. Kanamaru A, Takemoto Y, Kakishita E, et al FK506 treatment of graft-versus-host disease developing or exacerbating during prophylaxis and therapy with cyclosporine and/or other immunosuppressants. Bone Marrow Transplant. 1995;15:885-889.
12. Carnevale-Schianca F, Martin P, Sullivan K, et al Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:613-620.
13. Nagler A, Menachem Y, Ilan Y. Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment. J Hematother Stem Cell Res. 2001;10:411-417.
14. Couriel DR, Saliba R, Escalon MP, et al Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Brit J Haematol. 2005; 130:409-417.
15. Johnston LJ, Brown J, Shizuru JA, et al Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:47-55.
16. Jurado M, Vallejo C, Perez-Simon JA, et al Sirolimus as part of immunosuppressive therapy for refractory chronic graft- versus-host disease. Biol Blood Marrow Transplant. 2007; 13:701-706.
17. Antin JH, Kim HT, Cutler C, et al Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003;102:1601-1605.
18. Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:328-336.
19. Alcindor T, Gorgun G, Miller KB, et al. Immunomodulatory effects of extracorporeal photochemotherapy in patients with extensive chronic graft-versus-host disease. Blood. 2001;98:1622-1625.
20. Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood. 2002;100:941-947.
21. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft- versus-host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412-415.
22. Peritt D. Potential mechanisms of photopheresis in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:7-12.
23. Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998; 92:3098-3104.
24. Smith EP, Sniecinski I, Dagis AC, et al. Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs-host disease. Biol Blood Marrow Transplant. 1998;4:27-37.
25. Salvaneschi L, Perotti C, Zecca M, et al. Extracorporeal photochemotherapy for treatment of acute and chronic GVHD in childhood. Transfusion. 2001;41:1299-1305.
26. Messina C, Locatelli F, Lanino E, et al. Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. Brit J Haematol. 2003;122:118-127.
27. Seaton ED, Szydlo RM, Kanfer E, et al. Influence of extracor- poreal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood. 2003;102:1217-1223.
28. Apisarnthanarax N, Donato M, Korbling M, et al. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results. Bone Marrow Transplant. 2003;31:459-465.
29. Foss FM, DiVenuti GM, Chin K, et al. Prospective study of extracorporeal photopheresis in steroid-refractory or steroid- resistant extensive chronic graft-versus-host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35:1187-1193.
30. Rubegni P, Cuccia A, Sbano P, et al. Role of extracorporeal photochemotherapy in patients with refractory chronic graft- versus-host disease. Brit J Haematol. 2005;130:271-275.
31. Couriel D, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006;107:3074-3080.
32. Greinix HT, Socie G, Bacigalupo A, et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant. 2006;38:265-273.
33. Perseghin P, Galimberti S, Balduzzi A, et al. Extracorporeal photochemotherapy for the treatment of chronic graft-versus- host disease: Trend for a possible dose-related effect? Ther Apher Dial. 2007;11:85-93.
34. Owsianowski M, Gollnick H, Siegert W, et al. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis. Bone Marrow Transplant. 1994;14:845-848. Rossetti F, Zulian F, Dall’Amico R, et al. Extracorporeal photochemotherapy as single therapy for extensive, cutaneous chronic graft-versus-host disease. Transplant. 1995;59:149-151.
35. DallAmico R, Rossetti F, Zulian F, et al. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease. Brit J Haematol. 1997;97:848-854.
36. Abhyankar S, Godder K, Chiang K, et al. Extracorporeal photopheresis with UVADEX for the treatment of chronic graft- versus-host disease. Exp Hematol. 1998;26:32.
37. Child FJ, Ratnavel R, Watkins P, et al. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant. 1999;23:881-887.
38. Flowers MED, Van Besien, K, Apperley J, et al. A randomized single-blind study of extracorporeal photopheresis with UVADEX plus conventional therapy (CT) compared to CT alone in chronic GVHD. Blood. 2006;108:758 (abstract).
39. Greinix HT, Pohlreich D, Maalouf J, et al. A single-center pilot validation study of a new chronic GVHD skin scoring system. Biol Blood Marrow Transplant. 2007;13: 715-723.
40. Moriera AL, Sampaio EP, Znuidzinas A, et al. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med. 1993;177:1675-1680.
41. McHugh SM, Rifkin IR, Deighton J, et al. The immunosuppressive drug thalidomide induces T helper cell Type 1 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen-and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol. 1995;99:160-167.
42. Heney D, Norfolk DR, Wheeldon J, et al. Thalidomide treatment for chronic graft-versus-host disease. Brit J Haematol. 1991;78:23-27.
43. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992;326:1055-1058.
44. Parker PM, Chao N, Nademanee A, et al. Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604-3609.
45. Rovelli A, Arrigo C, Nesi F, et al. The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children. Bone Marrow Transplant. 1998;21:577-581.
46. Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide therapy in refractory chronic graft-versus-host disease. Bone Marrow Transplant. 2000;26:865-869.
47. Van de Poel MHW, Pasman PC, Schouten HC. The use of thalidomide in chronic refractory graft versus host disease. Neth J Med. 2001;59:45-49.
48. Kulkarni S, Powles R, Sirohi B, et al. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease. Bone Marrow Transplant. 2003;32:165-170.
49. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP. Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer. 2007;49:212-215.
50. Goldberg JD, Jacobsohn DA, Margolis J, et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. J Pediatr Hematol Oncol. 2003;25:584-588.
51. Arat M, Ilhan O, Iayan EA, Celebi H, Koc H, Akan H. Treatment of extensive chronic sclerodermatous graft-versus-host disease with high-dose immunosuppressive therapy and CD34+ autologous stem cell rescue. Blood. 2001;98:892-893.
52. Mookerjee B, Altomonte V, Vogelsang G. Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus. Bone Marrow Transplant. 1999;24:517-520.
53. Busca A, Saroglia EM, Lanino E, et al. Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bonemarrow transplantation. Bone Marrow Transplant. 2000;25:1067-1071.
54. Basara N, Kiehl MG, Blau W, et al. Mycophenolate mofetil in the treatment of acute and chronic GVHD in hematopoietic stem cell transplant patients: four years of experience. Transplant Proc. 2001;33:2121-2123.
55. Baudard M, Vincent A, Moreau P, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002;30:287-295.
56. Busca A, Locatelli F, Marmont F, et al. Response to mycophenolate mofetil therapy for refractory chronic graft-versus-host disease. Haemat. 2003;88:837-838.
57. Kim JG, Sohn SK, Kim DH, et al. Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic.stem cell transplant. Eur J Haematol. 2004;73:56-61.
58. Lopez F, Parker P, Nademanee A, et al. Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2005;11:307-313.
59. Krejci M, Doubek M, Buchler T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft- versus-host disease. Ann Hematol. 2005;84:681-685.
60. Slavin S. Successful treatment of autoimmune disease in (NZB/NZW)F1 female mice by using fractionated total lymphoid irradiation. Proc Natl Acad Sci U S A. 1979;76:5274-5276.
61. Valentine VG, Robbins RC, Wehner JH, et al. Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts. Chest. 1996;109:1184-1189.
62. Field EH, Rouse TM, Gao Q, et al. Association between enhanced Th2/Th1 cytokine profile and donor T-cell chimerism following total lymphoid irradiation. Hum Immunol. 1997;52:144-154.
63. Lan F, Zeng D, Higuchi M, et al. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-recative natural killer T cells. Biol Blood Marrow Transplant. 2003;9:355-363.
64. Socie G, Devergie A, Cosset JM, et al. Low-dose (one gray) total- lymphoid irradiation for extensive, drug-resistant chronic graft- versus-host disease. Transplant. 1990;49:657-658.
65. Bullorsky EO, Shanley CM, Stemmelin GR, et al. Total lymphoid irradiation for treatment of drug resistant chronic GVHD. Bone Marrow Transplant. 1993;11:75-76.
66. Robin M, Guardiola P, Girinsky T, et al. Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. Transplant. 2005;80:634-642.
67. Ullrich SE. Mechanisms underlying UV-induced immune suppression. Mutat Res. 2005;571:185-205.
68. Vogelsang GB, Wolff D, Altomonte V, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA) Bone Marrow Transplant. 1996; 17:1061-1067.
69. Aubin F, Brion A, Deconinck E, et al. Phototherapy in the treatment of cutaneous graft-versus-host disease. Transplant. 1995;1:151-155.
70. Volc-Platzer B, Honigsmann H, Hinterberger W, Wolff K. Photochemotherapy improves chronic cutaneous graft-versus- host disease. J Am Acad Dermatol. 1990;23:220-228.
71. Eppinger T, Ehninger G, Steinert M, Niethammer D, et al. 8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease. Transplant. 1990;50:807-811.
72. Atkinson K, Weller P, Rayman W, Biggs J. PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant. 1986;1:227-236.
73. Jampel RM, Farmer ER, Vogelsang GB, et al. PUVA therapy for chronic cutaneous graft-versus-host disease. Arch Dermatol. 1991;127:1673-1678.
74. Wolff D, Anders V, Corio R, et al. Oral PUVA and topical steroids for treatment of oral manifestations of chronic graft-versus-host disease. Photoderm Photoimmunol Photomed. 2004;20:184-190. Redding SW, Callander NS, Haveman CW, Leonard DL. Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:183-187.
75. Kerscher M, Volkenandt M, Meurer M, et al. Treatment of localized scleroderma with PUVA bath photochemotherapy. Lancet. 1994;343:1233.
76. Leiter U, Kaskel P, Krahn G, et al. Psoralen plus ultraviolet- A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft-versus-host disease. Photoderm Photoimmun Photomed. 2002;18:183-190.
77. Altman JS, Adler SS. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft- versus-host disease. J Am Acad Dermatol. 1994;31:505-507. Lindelof B, Sigurgeirsson B, Tegner E, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol. 1999; 141:108-112.
78. Grundmann-Kollmann M, Behrens S, Gross C, et al. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol. 2000;42:134-136.
79. Stander H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol. 2002;46:799-800.
80. Calzavara Pinton P, Porta F, Izzi T, et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft- versus-host disease. Haematologica. 2003;88:1169-1175.
81. Wetzig T, Sticherling M, Simon JC, et al. Medium dose long- wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant. 2005;35:515-519.
82. Enk CD, Elad S, Vexler A, et al. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant. 1998;22:1179-1183.
83. Van Dooren-Greebe RJ, Schattenburg A, Koopman RJJ. Chronic cutaneous graft-versus-host disease: successful treatment with UVB. Br J Derm. 1991;125:498-499.
84. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9:505-511. Canninga-van Dijk MR, Van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004;104:2603-2606.
85. Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006;108:756-762.
86. Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40:273-277.
87. Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH. Treatment of chronic graft-versus-host disease with clofazimine. Blood. 1997;89:2298-2302.
88. Marcellus DC, Altomonte VL, Farmer ER, et al. Etretinate therapy for refractory sclerodermatous chronic graft-versus-host disease. Blood. 1999;93:66-70.
89. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:327-334.
90. Bolanos-Meade J, Jacobsohn DA, Margolis J, et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol. 2005;23:2661-2668.
91. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion proteina s treatment for steroid refractory graft-versus- host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2006;82:45-52.
92. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee- Downey JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft- versus-host disease. Transplantation. 2002;73:665-667. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft- versus-host disease with daclizumab. Br J Haematol. 2001;112:820-823.
93. Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant. 2006;37:95-99.